In in vitro and in vivo models of lung cancer, EGCG has been found to resensitize tumor cells to Cisplatin (DDP)-based combination chemotherapy through DNMT and HDAC activity inhibition, and the subsequent re-expression of GAS1, TIMP4, ICAM1, and WISP2 genes [228]. Here, DNMT1 is linked to lung carcinoma.